IASLC 2011 Report – Erlotinib with or without MetMAb in the management of lung cancer
by Dr Sunil Upadhyay – Increased Met signalling in tumours can occur from increased levels of Hepatocyte Growth Factor (HGF), activating mutations within Met, and/or receptor over expression… read more.